Physician profile
Paul E Bernabe
NPI 1205835303
$7,725.70
in general payments reported to CMS, 2019-2025
45 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $848 · 2021: $1,085 · 2022: $1,204 · 2023: $1,324 · 2024: $1,385 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,813 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,220.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $749.76 | 2022-2025 | |
| Lilly USA, LLC | $746.36 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $672.49 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $603.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $544.01 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $448.80 | 2019-2025 | Gardasil 9, Vaxneuvance, Verquvo |
| Abbvie INC. | $437.36 | 2021-2025 | Vraylar |
| Pfizer INC. | $277.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.64 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.78 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $172.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $139.21 | 2021-2024 | Freestyle Libre |
| Amarin Pharma, INC. | $119.91 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.19 | 2019-2023 | Trintellix |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bernabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.